NASDAQ:MYOS

MYOS RENS Technology (MYOS) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$1.01
$11.40
52-Week Range
N/A
Volume
N/A
Average Volume
1.68 million shs
Market Capitalization
$16.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About MYOS RENS Technology

MedAvail Holdings, Inc. is a technology-enabled pharmacy company. It provides turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. The firm helps patients to optimize drug adherence, resulting in better health outcomes. The company is headquartered in Mississauga, Canada.

MYOS Stock News Headlines

Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Bio-active Peptides Market Size Dynamics 2023-2029
Will this $2 AI stock double overnight?
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
See More Headlines
Receive MYOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MYOS RENS Technology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/06/2019
Today
4/25/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MYOS
Fax
N/A
Employees
15
Year Founded
N/A

Profitability

Net Income
$-4,260,000.00
Net Margins
-277.82%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
$0.13 per share

Miscellaneous

Free Float
N/A
Market Cap
$16.70 million
Optionable
Not Optionable
Beta
1.08
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ed Kilroy
    President, Chief Executive Officer & Director
  • Ryan Ferguson
    Chief Financial Officer, Secretary & Treasurer
  • Fraser Mackay
    Chief Information Officer
  • David John Rawlins
    Chief Commercial Officer
  • Neil Prezioso
    Chief Pharmacy Officer

MYOS Stock Analysis - Frequently Asked Questions

How were MYOS RENS Technology's earnings last quarter?

MYOS RENS Technology Inc. (NASDAQ:MYOS) released its quarterly earnings data on Tuesday, August, 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by $0.01. The company earned $0.15 million during the quarter, compared to analysts' expectations of $0.14 million. MYOS RENS Technology had a negative net margin of 277.82% and a negative trailing twelve-month return on equity of 166.68%.

What other stocks do shareholders of MYOS RENS Technology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MYOS RENS Technology investors own include Chesapeake Energy (CHKAQ), Catalyst Pharmaceuticals (CPRX), Biocept (BIOC), Global Blood Therapeutics (GBT), Sorrento Therapeutics (SRNE), T2 Biosystems (TTOO), AbbVie (ABBV), AcelRx Pharmaceuticals (ACRX) and BioLineRx (BLRX).

This page (NASDAQ:MYOS) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners